Our Company: Developing Oncology Therapeutics to Improve Cancer Care

Our lead therapeutic candidate, PCM-075, provides us the opportunity to bring a first-in-class PLK1 inhibitor to the market for the treatment of patients with acute myeloid leukemia (AML). The pharmacokinetic and pharmacodynamic properties of PCM-075 may provide a more selective approach for targeting the rapid mitosis that is characteristic of AML, as well as avoid some of the debilitating toxicities seen with standard chemotherapy drugs.


Oncology Therapeutics, Precision Medicine in cancer - AML Ribbon
What are the Key Statistics About AML?

The American Cancer Society’s estimates for leukemia in the United States for 2017 are:

  • About 21,380 new cases of acute myeloid leukemia (AML). Most will be in adults.
  • About 10,590 deaths from AML. Almost all will be in adults.
Oncology Therapeutics, Precision Medicine in cancer - NEXTCOLLECT Box
Coming Soon NextCollect

NextCollect is a first of its kind, proprietary urine collection and DNA preservation system. By housing the preservative solution in the reservoir cap, we have created the first ever automated DNA stabilizing device for urine collection. For more information, please email bd@trovagene.com.

Oncology Therapeutics, Precision Medicine in cancer - LD Micro
Marcum 2017 MicroCap Conference

Trovagene CEO, Bill Welch, will be presenting at the conference on Thursday, June 15th, at 3:00 pm EDT at the Grand Hyatt Hotel in NY. The presentation will be webcast live at http://wsw.com/webcast/marcum5/trov and a replay of the presentation will be available and archived for 90 days.